Receptor tyrosine kinase (RTK) signaling promotes the growth and progression of glioblastoma (GBM), a highly aggressive type of brain tumor. We previously reported that decreased miR-218 expression in GBM directly promotes RTK activity by increasing the expression of key RTKs and their signaling mediators, including the RTK epidermal growth factor receptor (EGFR), phospholipase C-g1 (PLCg1), and the kinases PIK3CA and ARAF. However, increased RTK signaling usually activates negative feedback mechanisms to maintain homeostasis. We found that decreased miR-218 expression in GBM cells also increased the expression of genes encoding additional upstream and downstream components of RTK signaling pathways, including the RTK platelet-derived growth factor receptor a (PDGFRa) and the kinases ribosomal S6 kinase 2 (RSK2) and S6 kinase 1 (S6K1), that collectively overrode the negative feedback mechanism. Furthermore, increased RTK signaling itself suppressed miR-218 expression. Mass spectrometry and DNA pull-down identified binding of signal transducer and activator of transcription 3 (STAT3) along with the transcriptional repressor BCL2-associated transcription factor 1 (BCLAF1) directly to the miR-218 locus. These data identify previously unknown feedback loops by which miR-218 repression promotes increased RTK signaling in high-grade gliomas.
INTRODUCTION
Glioblastomas (GBM) are the most common malignant brain tumors, with a median patient survival of 12 to 14 months after aggressive surgery, radiation, and chemotherapy (1) (2) (3) (4) . Extensive research has begun to elucidate the molecular mechanisms underlying GBM initiation and progression. Large-scale genomic analyses initiated by The Cancer Genome Atlas (TCGA) and other groups (5, 6) classified GBM into multiple subtypes, of which proneural and mesenchymal GBM compose the two major classes. Human gliomas typically exhibit recurring abnormalities in genes encoding the tumor suppressors RB (retinoblastoma protein) and p53, the receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), and downstream RTK pathway components, including the kinases AKT and mitogenactivated protein kinase (MAPK) and the guanosine triphosphatase RAS (7) . Furthermore, activating mutations of phosphatidylinositol 3-kinase (PI3K) are observed in nearly all GBM patients (8) . We recently demonstrated that RTK signaling in GBM is regulated by the microRNA (miRNA) miR-218 (9), the abundance of which is decreased relative to normal brain tissue in all GBM patient samples tested (10) . Specifically, miR-218 binds to and inhibits the expression of mRNAs encoding critical signaling effectors, including EGFR and phospholipase C-g1 (PLCg1); thus, miR-218 repression promotes RTK signaling in GBM.
To ensure homeostatic regulation in healthy cells, RTK signaling is tightly controlled by negative feedback mechanisms. For example, increased mammalian target of rapamycin complex 1 (mTORC1) activation impairs PI3K stimulation by decreasing the amounts of IRS1/2 (insulin receptor substrate 1/2) and PDGFR (8, 11) , whereas mTORC1 inhibition increases PDGFR accumulation and MAPK or AKT activation in GBM (8, 12) . Moreover, a characteristic feature of ribosomal S6 kinase 2 (RSK2)-deficient mice is increased and sustained extracellular signal-regulated kinase (ERK) activation in skeletal muscles, suggesting that RSK2 may also contribute to negative feedback control of upstream ERK signaling (13) . Multiple studies have shown that RTK pathway signaling is subject to substantial feedback regulation in GBM and other cancers (12, 14) . Because miR-218 repression increases the abundance of various RTK pathway components (9), we investigated whether miR-218-dependent modulation of RTK signaling also engages inhibitory feedback control. Our data revealed that miR-218 repression reduced inhibitory feedback regulation by increasing key effectors, including RSK2, S6 kinase 1 (S6K1), and PDGFRa, thereby sustaining enhanced RTK pathway activity in GBM cells. We further define a novel mechanism whereby RTK signaling, in turn, promotes miR-218 repression in a signal transducer and activator of transcription 3 (STAT3)-dependent manner, revealing the existence of complex, interacting feedback loops regulating RTK activation in GBM.
effectors of ERK and mTORC1, respectively (Fig. 1B) . Total RSK and S6K1 protein abundance was also reduced by miR-218 expression (Fig.  1B) , suggesting that miR-218 inhibits their corresponding mRNAs directly. Indeed, the miR-218 mimic repressed the activity of luciferase reporter gene constructs containing either RSK2 or S6K1 3′ untranslated region (3′UTRs), an effect lost upon mutation of the corresponding miR-218 seed sequences (Fig. 1C and fig. S1A ). Furthermore, transient or stable miR-218 expression reduced RSK2 and S6K1 abundance in GBM cells and glioma stem-like cells (GSCs), respectively ( Fig. 1, D and E, and fig. S1B). We performed intracranial orthotopic xenograft assays by transplanting T3691 GSCs expressing either scrambled (SCR) or miR-218 RNAs and observed reduced RSK2 and S6K1 transcripts in Tum-3691-218 brain tumor B2  B3  B4  B5  B6  B7  B8  B9  B10  B11  B12  G1  G2  G3  G4  G5  G6  G7  G8  G9  G10  G11  G12  G13  G14  G15  G16  G17  G18  G19  G20  G21  G22  G23  G24  G25  G26  G27  G28  G29  G30   Relative expression   Normal brain samples  Glioblastoma samples   RSK2   0   1   2   3   4   5   6   7   8   9   B1  B2  B3  B4  B5  B6  B7  B8  B9  B10  B11  B12  G1  G2  G3  G4  G5  G6  G7  G8  G9  G10  G11  G12  G13  G14  G15  G16  G17  G18  G19  G20  G21  G22  G23  G24  G25  G26  G27  G28  G29 (E) Western blotting and densitometry of RSK2 and S6K1 protein accumulation after stable expression of pre-miR-218 in T3691 GSCs. (F) Analysis of RSK2 and S6K1 mRNA isolated from intracranial orthotopic xenografts derived from T3691 GSCs expressing miR-218 (Tum-3691-218) relative to those expressing a scrambled RNA (Tum-3691-SCR) (n = 3 independent tumors). (G) Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) of RSK2 and S6K1 expression in GBM patient samples (red; G1 to G30) and normal brain tissue (green; B1 to B12). (H) Immunohistochemical analysis of RSK2 and S6K1 abundance in GBM (n = 60) and normal brain tissue microarrays (n = 40). Scale bar, 20 mm. *P < 0.05, **P < 0.005, and ***P < 0.0005. Data are means ± SEM from n, as stated in each panel.
sections (Tum-3691-SCR compared with Tum-3691-218 tumors) (Fig. 1F) . Notably, RSK2 and S6K1 mRNAs were increased in human GBM patient samples (n = 30) compared to 12 normal brain tissues (Fig. 1G) , and immunohistochemical assays demonstrated increased RSK2 and S6K1 protein accumulation in human GBM tissues (35 of 35 cases and 25 of 25 cases, respectively) (Fig. 1H) . We then compared RSK2 and S6K1 expression between proneural and mesenchymal GBM subtypes. S6K1 mRNA abundance was higher in both mesenchymal and proneural GBM than in normal brain tissue samples ( fig. S1 , C and D). However, we did not observe dramatic differences in RSK2 expression between normal tissue and both GBM subtypes. There could be numerous reasons for this observation. For example, miR-218-mediated regulation of RSK2 is likely to be only one of multiple factors that control the expression of this gene. It should be noted that although RSK2 transcript accumulation is similar between normal tissue and both GBM subtypes, we did see a marked and consistent increase of RSK2 protein in GBM patient samples compared to that in normal brain tissue (Fig. 1H ). RSK2 mRNA amounts were higher in mesenchymal tumors when compared to proneural tumors ( fig. S1D ). This is noteworthy because we have previously shown that miR-218 repression is also more pronounced in mesenchymal than in proneural GBM (9), indicating an inverse correlation between the two, consistent with miR-218 regulation of RSK2. Finally, small interfering RNA (siRNA)-mediated RSK2 or S6K1 knockdown promoted staurosporine-mediated cell death ( fig. S1 , E to H), as did the miR-218 mimic in GBM cells ( fig. S1I ). Because staurosporine (a protein kinase inhibitor) induces apoptosis, these results indicate that miR-218, RSK2, and S6K1 operate in a common pathway. In addition to our previous studies (9) , the data reveal a pattern in which miR-218 controls multiple RTK pathway components, including both cell surface receptors and downstream effectors.
miR-218 modulates RTK feedback regulatory mechanisms by directly regulating PDGFRa
Regulatory feedback mechanisms that modulate RTK activity have a role in GBM and other cancers (12, 14) . Because both S6K1 and RSK2 enhance ERK activity, we tested whether miR-218-mediated S6K1 and RSK2 inhibition might result in compensatory ERK reactivation. Expression of the miR-218 mimic did not increase the phosphorylation of ERK in GBM cells ( Fig. 2A) , although S6K1 or RSK2 knockdown by siRNAs or short hairpin RNAs (shRNAs) did, as expected ( Fig. 2B and fig. S2A ). These data suggest that miR-218 regulates additional targets that uncouple RTK signaling from established regulatory feedback control. Because miR-218 suppresses the abundance of S6K1 (an mTORC1 substrate) and Rictor (a critical mTORC2 component) (15) , we investigated the role of overall mTOR signaling in these phenotypes. Because hyperactivation of AKT and mTORC1 signaling suppresses PDGFRa accumulation as a compensatory mechanism (8, 11), we investigated whether miR-218 regulates PDGFRa activity. To mimic the combined effects of miR-218 on mTORC1 and mTORC2, we used a dual mTOR kinase inhibitor (AZD8055). , and RSK2 mRNA in U373 cells transfected with a control or miR-218 inhibitor. *P < 0.05, **P < 0.005, and ***P < 0.0005. Data are means ± SEM from three experiments.
but this effect was largely blocked by miR-218 (Fig. 2D) . Similarly, shRNAmediated inhibition of S6K1 coupled with miR-218 treatment reduced the levels of PDGFRa and phosphorylated AKT when compared to shS6K1 or the miR-218 mimic alone ( fig. S2B ). S6K1 suppression by itself was not sufficient to increase PDGFRa abundance in U373 cells ( fig. S2B ). Because the abundance of PDGFRa was reduced in response to the miR-218 mimic ( Fig. 2D and fig. S2B ), we hypothesized that PDGFRa could also be a direct miR-218 target. PDGFRa 3′UTR luciferase reporter activity, mRNA, and protein were all substantially repressed by miR-218 ( Fig.  2E and fig. S2 , C and D). Furthermore, PDGFRa mRNAs were decreased in orthotopic Tum-3691-218 tumors compared to Tum-3691-SCR samples (Fig. 2F) . Overall, the expression of PDGFRa mRNA in GBM patient samples was greater than that in normal brain tissue ( fig. S2E ). These data indicate that PDGFRa is a direct miR-218 target. Combined with our aforementioned data, the results so far suggest that increased PDGFRa protein in miR-218-deficient GBM cells may reduce feedback inhibition from enhanced S6K1 and RSK2 signaling, thereby promoting sustained ERK activation ( Fig.  2A) . Finally, miR-218 inhibition modestly enhanced the expression of RSK2, S6K1, and PDGFRa (Fig. 2G ), highlighting the importance of miR-218 repression in overriding the RTK feedback circuit. Notably, combined knockdown of RSK2 and PDGFRa or S6K1 and PDGFRa was not sufficient to abrogate the feedback ERK reactivation mechanism ( fig. S2F ). These data indicate that inhibition of only two miR-218 targets cannot quench feedback reactivation, likely because of compensation by other RTK pathway components that are also miR-218 targets (9).
miR-218 repression promotes RTK activity by attenuating feedback inhibitory mechanisms
We next investigated whether miR-218 deficiency overrides feedback inhibitory mechanisms more generally in GBM cells. To test this hypothesis, we used a phosphokinase antibody array to screen the activity of RTK signaling pathway components. Our previous studies demonstrated that miR-218-mediated effects were enhanced by ischemic or chemotherapeutic stresses that mimic the GBM tumor microenvironment (9) . Temozolomide (TMZ) is a widely used GBM chemotherapeutic agent. Consequently, we challenged U87MG cells stably expressing scrambled (U87-SCR) or miR-218 (U87-218) RNAs with serum-free medium (SFM) or a combination of SFM and TMZ for 72 hours and evaluated the phosphorylation status of various RTK signaling members (Fig. 3, A 
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Normalized intensity U87-SCR controls (Fig. 3, A to D) . The reduction in RTK component phosphorylation was more pronounced when cells were exposed to SFM and TMZ combined than when cells were exposed to SFM alone (Fig. 3 , A to D). These results indicate that miR-218 repression increases the basal activity of multiple RTK pathway effectors to override feedback inhibitory mechanisms, favoring sustained RTK signaling in GBM (Fig. 3E ).
RTK activation, in turn, suppresses miR-218 expression in GBM
Given that low miR-218 resulted in a cumulative increase in RTK pathway flux, we next investigated whether RTK activation might regulate miR-218 in a reciprocal fashion in GBM. We hypothesized that active RTK signaling would repress miR-218 transcription. Pharmacological inhibition of RTK activity using a pan-RTK inhibitor (sunitinib malate); a PDGFR, vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) receptor inhibitor (SU6668); or an EGFR inhibitor (AG-1478) increased the expression of miR-218 in U87MG and U373 cells and T4121 GSCs (Fig. 4, A and B) . Similarly, U87MG cells expressing a plasmid encoding the constitutively active EGFR variant III (EGFRvIII) significantly reduced miR-218 expression (Fig. 4C ). This effect was lost when a "dead kinase" (DK) EGFRvIII construct (16) was used (Fig. 4C) . Similar results were obtained using LN18 and U373 cells (Fig. 4D and fig. S4A ). In addition, we determined that ligand-induced activation of the EGFR signaling pathway (by treatment with EGF) reduced miR-218 expression in U373 and LN18 cells (Fig. 4E) . Analysis of TCGA data from primary human GBM revealed that miR-218 transcription is lower in samples with high EGFR abundance (Fig. 4F ) compared to samples with low EGFR. In aggregate, these findings indicate that RTK signaling represses the miR-218 locus.
To explore the mechanism(s) of RTK signaling-mediated effects on miR-218 expression, we examined basic miR-218 transcriptional regulation in GBM cells. miR-218 is encoded in intronic sequences of the SLIT2 and SLIT3 genes. We observed a significantly higher positive correlation between miR-218 and SLIT2 expression than between miR-218 and SLIT3 expression in GBM patient samples from the TCGA (fig. S3, A and B) . Basal miR-218 expression also correlated more closely with SLIT2 than SLIT3 in various GBM cell lines ( fig. S3C ), indicating that miR-218 predominantly originates from an intronic sequence within SLIT2 in this context. Both host genes are silenced by methylation in GBM (17, 18) , suggesting a potentially epigenetic basis for miR-218 suppression by RTK signaling. TCGA data revealed variable DNA methylation patterns across the SLIT2 locus, with substantial methylation intensity observed at the position corresponding to miR-218 and, to a lesser extent, at the SLIT2 transcription start site (Fig. 4G) . Because previous studies showed that DNA methyltransferase 1 (DNMT1) and histone methyltransferase EZH2 play an important role in SLIT2 suppression by methylation (19, 20) , it seemed likely that DNMT1 and EZH2 result in the same repression of the miR-218 locus. Notably, treatment with the demethylating agent 5-azacytidine or an EZH2 inhibitor [3-deazaneplanocin A (DZNep)] produced comparable increases in miR-218 and SLIT2 transcript levels ( fig. S4 , B and C), suggesting that DNMT1 and EZH2 exert epigenetic silencing along the SLIT2/miR-218 genomic region.
We then further investigated whether EGFRvIII activation contributes to epigenetic miR-218 silencing by regulating these epigenetic modifying factors that mediate miR-218 silencing. Indeed, high EGFRvIII activation modestly increased DNMT1 protein accumulation in U87MG and LN18 cells (Fig. 4H) , although the abundance of EZH2 and SUZ12 was not significantly altered. To define EGFR downstream effectors that potentially regulate DNMT1, we screened a cohort of inhibitors (such as those blocking AKT, ERK, STAT3, and c-Jun N-terminal kinase activity) targeting various RTK pathway members and identified STAT3 and AKT as potential intermediates that promote DNMT1 expression ( fig. S4D ). Furthermore, shRNA-mediated STAT3 knockdown reduced DNMT1 mRNA and protein ( fig. S4 , E and F), consistent with a recent study demonstrating that STAT3 induces DNMT1 in malignant T lymphocytes (21) . Notably, EZH2 abundance was also reduced by AKT and STAT3 inhibition ( fig.  S4, D to F) . Our data suggest a model wherein RTK signaling represses the miR-218 locus, probably through increased methylation, in a STAT3-dependent manner.
STAT3 represses miR-218 in GBM
To test our model directly, we inhibited STAT3 in LN18 cells with shRNAs, which resulted in higher miR-218 expression (Fig. 5A ). STAT3 knockdown did not alter expression of the host gene SLIT2 (Fig. 5B ) but instead increased the abundance of primary-miR-218 (pri-miR-218) transcripts in LN18 cells, as well as in T3832, T4302, and T4121 GSCs (Fig. 5C and  fig. S5, A and B) . This differential regulation appeared to be independent of DNA methylation status (or EZH2 activity) because miR-218 and SLIT2 exhibited concurrent expression changes upon treatment with inhibitors of DNMT1 or EZH2 ( fig. S4, B and C) . Analysis of the SLIT2 genomic locus (using http://genome.ucsc.edu/cgi-bin/hgGateway) revealed a potential STAT3 binding site 4 kb downstream of the miR-218 transcriptional start site, which we designated as the "miR-218 + 4 kb" site. Accordingly, chromatin immunoprecipitation (ChIP) analysis detected robust STAT3 binding to the miR-218 + 4 kb site (Fig. 5D) , suggesting that STAT3 directly represses the miR-218 locus. Ectopic expression of STAT3 in U373 cells significantly reduced primary and mature miR-218 abundance (Fig. 5E) . Therefore, our data suggest that miR-218 expression can be regulated by DNA methylation as part of the SLIT2 locus and independently by STAT3 repression and that RTK signaling affects particularly the methylation-independent regulation of miR-218 expression.
To identify other factors that interact with STAT3 to mediate miR-218 repression, we performed DNA pull-down assays coupled with proteomic analysis. Briefly, a 100-base pair (bp) fragment spanning the miR-218 + 4 kb site was biotin-labeled (Fig. 5F ), incubated with LN18 nuclear extracts, and precipitated with streptavidin-agarose beads. After confirming the presence of STAT3 in the precipitate by immunoblot analysis (Fig. 5F ), we performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to identify additional bound proteins. From a list of more than 200 peptides detected by this analysis, we focused on proteins with known repressor functions, including PHB2, BRG1, CEBPZ, XRN2, and BCL2-associated transcription factor 1 (BCLAF1). To assess the role of these targets in mediating miR-218 suppression, we silenced their expression individually using shRNAs and analyzed their effects on pri-miR-218 transcription. BCLAF1 knockdown specifically increased pri-miR-218 but not SLIT2 expression in GSCs (Fig. 5, G and H, and fig. S5C ), similar to the results obtained by STAT3 knockdown. We further confirmed increased enrichment of BCLAF1 bound to the miR-218 + 4 kb region using the biotin-streptavidin DNA pull-down assay, as well as ChIP using a BCLAF1 antibody (Fig. 5, F and I ). Finally, we silenced STAT3 to specifically investigate its role in BCLAF1 enrichment at the miR-218 + 4 kb region and determined that the presence of BCLAF1 is completely STAT3-dependent (Fig. 5J) . Coimmunoprecipitation experiments failed to reveal a direct association between STAT3 and BCLAF1, suggesting that STAT3 is necessary for BCLAF1 recruitment to this site, but that other factors must also be involved. In summary, as shown in Fig. 5K , activated RTK signaling suppresses miR-218 expression by increasing the binding of STAT3 and BCLAF1 to the miR-218 + 4 kb region. Their binding attenuates miR-218-mediated suppression of the RTK pathway and therefore forms a selfreinforced feedback loop.
DISCUSSION
Genome-wide analyses of GBM patient samples have identified cumulative genetic and epigenetic changes during tumor development (22) (23) (24) . During this multistep process, tumor suppressor genes are silenced, oncogenes are activated, and miRNA expression is altered to facilitate tumor cell survival and growth. miRNAs are of great interest because of their ability to target numerous genes and their use in discovering biological mechanisms. Our experiments reveal that miR-218 affects the feedback regulatory components of RTK signaling (8, 11, 25) and that low miR-218 expression increases the abundance of multiple RTK pathway components, including cell surface receptors and downstream effectors. Together, these effects serve to overcome the homeostatic feedback inhibitory mechanisms that normally operate in cells with active RTK signaling. This regulatory phenomenon may have important implications for RTK signal transduction; for example, mTORC1 activation has been shown to initiate a negative feedback loop stemming from S6K1, leading to PI3K and MAPK inhibition (12) . Therefore, GBM cells with high mTORC1 activity could experience inhibitory checks at the AKT and ERK levels. Our data reveal a previously unreported mechanism whereby low miR-218 expression increases the baseline abundance of S6K1 and RSK2 to alleviate feedback inhibition and to sustain RTK pathway activity in GBM cells.
In addition to these downstream targets, miR-218 also inhibits PDGFRa (26) , an important feedback regulatory component of the PI3K-AKT signaling pathway. Previous studies have indicated that hyperactivation of PI3K-AKT significantly suppresses PDGFR expression in an mTOR-dependent manner (11) . Because PI3K-AKT signaling is highly active in GBM (27) , this could lead to PDGFR inhibition as a compensatory mechanism for maintaining tumor microenvironmental homeostasis, especially during depletion of O 2 and nutrients. Our results indicate that reduced miR-218 abundance enables tumor cells to modestly increase the amount of PDGFR, without triggering strong feedback inhibitory responses. In a similar fashion, miR-296 expressed in primary tumor endothelial cells has been shown to reduce the abundance of hepatocyte growth factorregulated tyrosine kinase substrate (HGS), resulting in increased accumulation of VEGF receptor 2 and PDGFR, which are targets of HGS-mediated degradation (28) . These studies indicate the importance of miRNAs in fine-tuning the expression of RTK regulatory components to sustain signaling without activating inhibitory feedback responses.
The expression of miR-218 is downregulated in all gliomas when compared to normal brain tissue samples, but the repression is more pronounced in mesenchymal GBM when compared to proneural subtypes (9). Our results indicate that STAT3 mediates a repressive effect on miR-218 expression in GBM and identify a specific STAT3 binding site closely linked to the miR-218 locus. STAT3 is predominantly known as a transcriptional activator, but multiple studies have shown that STAT3 can also act as a repressor (29, 30) . Nevertheless, relevant proteins required for the repressive activity of STAT3 have not been previously identified. Notably, STAT3 is a master regulator of a mesenchymal gene signature in gliomas (31) , and we propose that STAT3 binding could be responsible for the highly repressed state of miR-218 in mesenchymal GBM. We also identified increased recruitment of BCLAF1 to the STAT3 binding region. BCLAF1 is a transcriptional repressor that interacts with antiapoptotic members of the BCL2 family (32) . Notably, recent studies have indicated that BCLAF1 also interacts with BRCA1 and mediates the formation of a BRCA1-mRNA splicing complex during DNA damage (33) . By direct interaction with BCLAF1, BRCA1 recruits the splicing machinery and favors precursor mRNA splicing of BRCA1 target genes, which promotes transcript stability (33) . It is possible that an intronic region spanning the miR-218 locus is also preferentially spliced out through a BCLAF1-dependent cotranscriptional splicing event (33) . Collectively, this study identifies complex regulatory feedback loops by which miR-218 repression increases the abundance of multiple RTK pathway components in GBM, thereby overcoming inhibitory feedback mechanisms that would otherwise restrain RTK signaling. In turn, increased RTK signaling increases the expression of the gene encoding STAT3, which directly binds to the miR-218 locus, along with BCLAF1, and represses its expression to reinforce low miR-218 abundance in GBM (Fig. 5K) .
MATERIALS AND METHODS

Cell culture reagents and treatments
GSCs were grown in neurobasal medium and supplemented with B27 (1:50; Invitrogen), EGF (20 ng/ml; Sigma), and basic FGF (20 ng/ml), as previously described (34) . U87MG, U373, LN18, and T98G cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics. U87MG DK and EGFRvIII cells were provided by M. J. Lazzara (University of Pennsylvania). Staurosporine (1 to 2 mM; Cell Signaling) was used to induce cell death for 4 hours. To create a chemotherapeutic microenvironmental stress, we combined serum starvation with TMZ (250 mM) for 72 hours.
To activate the MAPK signaling pathway, human EGF (100 ng/ml) was used for 30 min. A dual mTOR kinase inhibitor, AZD8055 (Selleck Chemicals), was used at a final concentration of 500 nM. The RTK inhibitors sunitinib malate and AG-1478 hydrochloride (Tocris Bioscience) were used at a final concentration of 10 mM for 24 hours. The RTK inhibitor SU6668 (Tocris Bioscience) was used at a final concentration of 10 mM in T4121 cells and 50 mM in U373 cells for 24 hours. For inhibiting methylation, 5-azacytidine was used at a final concentration of 10 mM for 6 days, and dosing medium was changed every 2 days. EZH2 inhibitor (DZNep) was used for 24 hours at a final concentration of 10 mM.
GBM patient samples
GBM patient tissue sections (n = 30) and control specimens (n = 12) were obtained from formalin-fixed, paraffin-embedded tissues (Department of Pathology and Laboratory Medicine, University of Pennsylvania). The control sections consisted of temporal lobectomy specimens obtained from patients with intractable epilepsy and showed histopathologic evidence of mild to focally moderate gliosis but no lesions. All the GBM blocks contained more than 95% tumor cells.
Western blot, immunohistochemistry, and immunofluorescence
On the basis of the appropriate experimental time points, cells were lysed by standard procedure in lysis buffer containing a protease inhibitor cocktail. Protein lysates (50 mg) were resolved on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels followed by immunoblot detection and visualization with an enhanced chemiluminescence kit (PerkinElmer). Antibodies and concentrations used for immunoblots were as follows: BCLAF1 (#A300-608, Bethyl Laboratories; 1:1000); DNMT1 (#ab1353, Abcam; 1:1000); and rabbit RSK (#9355), rabbit p-RSK, rabbit S6K1 (#9202), rabbit p-S6K1 (#9208), rabbit b-tubulin (#2146), rabbit RSK2 (#9340), rabbit ERK1/2 (#4695), rabbit p-ERK1/2 (#9101), rabbit p-AKT (S473, #9271), rabbit AKT (#9272), rabbit PDGFRa (#3164), rabbit EGFR (#4267), rabbit p-EGFR (#3777), rabbit EZH2 (#5246), rabbit SUZ12 (#3737), rabbit p-STAT3 (#9145), and mouse STAT3 (#9139) (all from Cell Signaling; 1:1000 dilution). For immunohistochemical analysis, brain GBM and normal tissue array (40 cases/80 cores) was purchased from Biomax (GL806). The paraffin-embedded tissue array processing for immunohistochemical analysis was performed as described earlier (9) . Antibodies and concentrations used for immunohistochemistry and immunofluorescence were as follows: rabbit S6K1 (1:50; Cell Signaling) and rabbit RSK2 (1:100; Cell Signaling).
RNA from orthotopic brain tumor xenografts
All experiments in mice were approved by the University of Pennsylvania Institutional Animal Care and Use Committee and performed in accordance with the National Institutes of Health (NIH) guidelines. Intracranial xenograft tumor assays were performed in nu/nu mice, as described (35) . Briefly, GSC T3691 tumor spheres (50,000 cells; T3691-SCR or T3691-218) in a total volume of 5 ml were implanted into the right frontal lobes of nude mice. The animals were sacrificed 25 days after implantation upon exhibition of neurological symptoms. RNA was isolated from frozen brain tissue sections.
Luciferase reporter assay
The 3′UTRs of RSK2, S6K1, and PDGFRa were cloned into pMIR-REPORT miRNA expression reporter vector (ABI). Twenty-four hours after transfection with negative or miR-218 mimics in T98G cells, the respective plasmids were transfected into cells with FuGENE 6 transfection reagent (Roche) in 24-well plates. Renilla luciferase plasmid was cotransfected and used to normalize the firefly luciferase values expressed from the pMIR-REPORT expression vector. Luciferase assays were performed using the dual luciferase protocol (Promega) at 48 hours after transfection of the corresponding plasmids containing the 3′UTRs. For testing the role of specific seed sequences in the 3′UTR of miR-218 target genes, mutations were introduced into the miR-218 binding seed sequences and compared to the wild-type sequence (table S2) . The duplex sequences spanning the miR-218 binding sites for the respective target genes were cloned into pMIR-REPORT expression vector for further luciferase analysis.
Quantitative RT-PCR
To isolate total RNA, miRNeasy Mini Kit (Qiagen) was used and the RNA was reverse-transcribed into complementary DNA (cDNA) using High Capacity RNA-to-cDNA Kit (ABI). Analysis of miR-218 expression was performed using the TaqMan MicroRNA Reverse Transcription Kit (ABI) according to the manufacturer's instructions. TaqMan primers (purchased from Applied Biosystems) were used to measure the abundance of all the transcripts, and analyses were performed on the ABI 7900HT system. All target mRNA expression was normalized to that of 18S. Sequences for the 18S SYBR green primer set were as follows: h18sF, 5′-GAATTCCC-AGTAAGTGCGGG-3′; h18sR, 5′-GGGCAGGGACTTAATCAACG-3′.
The qRT-PCR data showed the average mRNA abundance from three independent RNA extractions and reverse transcription reactions with error bars showing SEM.
Transient or stable overexpression of miR-218, siRNAs, or shRNAs
For cell culture studies, cells were transfected with a control or a mature miR-218 mimic (Dharmacon) with HiPerfect reagent (Invitrogen). For viral transduction, cells were transduced with lentiviral particles bearing pCDHmiR-218, pLKO1-shRSK2, and pLKO1-shS6K1 plasmids generated in human embryonic kidney (HEK) 293T cells. HEK 293T cells were transfected with pCDH-miR-218/SCR (System Biosciences), pLKO1-shRSK2, pLKO1-shS6K1 (Open Biosystems), and viral packaging plasmids, according to the FuGENE reagent protocol (Roche). For siRNA experiments, siRNAs were purchased from Dharmacon (siRSK2, ON-TARGETplus SMARTpool human RPS6KA3; siS6K1, ON-TARGETplus SMARTpool human RPS6KB1). Similar to miRNA mimics, cells were transfected with "negative" or siRNA against the gene of interest. The efficiency of siRNAs and shRNAs was tested by Western blotting.
Phosphokinase array
The human phosphokinase array was purchased from R&D Systems. U87-SCR or U87-218 cells exposed to SFM or SFM and TMZ for 72 hours were solubilized in Lysis Buffer 6, and the concentration of the proteins was determined using standard bicinchoninic acid assay. A total of 45 antibodies (table S1) printed on two separate nitrocellulose membranes were used for this study. Briefly, the membranes were blocked with Array buffer 1 and then incubated with cell lysates overnight at 4°C. The membranes were washed and then incubated with the detection antibody cocktail for 2 hours at room temperature. The membranes were washed further, and Chemi Reagent mix was used for autoradiographic detection of protein spots.
Biotinylated DNA pull-down analysis
The proteins bound to specific oligos [genomic region with a STAT3 binding site that is 4 kb downstream of the miR-218 locus (http://genome.ucsc. edu/cgi-bin/hgGateway)] were isolated according to a protocol reported by Wu (36) . Briefly, nuclear proteins were extracted according to standard methods, and the concentration of the sample was determined. The duplex biotinylated oligos (table S3) were incubated with streptavidin-agarose bead suspension and nuclear proteins for 2 hours. The mixture was centrifuged and the supernatant was removed. The beads were washed followed by suspension in 2× Laemmli sample buffer and incubated at 95°C for 5 min. The beads in Laemmli buffer were centrifuged, and the supernatant was resolved on an SDS-PAGE gel for Western blotting for the indicated proteins.
LC-MS/MS analysis
The protein sample extracted using the biotinylated DNA pull-down assay (as described above) was run on a resolving gel. The LC-MS/MS analysis was performed at the Proteomics Core Facility at the Wistar Institute. Briefly, the gel band was excised and digested with trypsin, and the digests were analyzed by LC-MS/MS on an LTQ Orbitrap XL mass spectrometer. The MS/MS spectra generated were searched against a human database (http://uniprot.org) using SEQUEST. Only proteins identified by two or more peptides (high confidence) were included, and common contaminants (for example, keratins) were removed.
Chromatin immunoprecipitation
ChIP assays were completed using Imgenex QuikChIP kit from Novus Biologicals. Briefly, 5 million LN18 cells were cross-linked with 1% formaldehyde for 10 min at 37°C. The cross-linking reaction was stopped by glycine followed by cell lysis using SDS buffer containing protease inhibitor cocktail. Cell lysates were sonicated into DNA fragments of 200 to 1000 bp in size and immunoprecipitated with immunoglobulin G, STAT3 (Cell Signaling), or BCLAF1 (Bethyl Laboratories) antibodies followed by incubation with DNA/protein A/protein G agarose. The immunoprecipitated DNA fragments were washed with a series of buffers, de-crosslinked at 65°C, and purified using QIAquick PCR purification kit (Qiagen). Semiquantitative PCR was performed using the following primers: 218-STAT3 + 4 kb, 5′-TGCCTTCTGGCAAGCATTGT-3′ and 5′-TCCAAGGGTCT-CCAGGAGTAT-3′; 18S, 5′-GAATTCCCAGTAAGTGCGGG-3′ and 5′-GGGCAGGGACTTAATCAACG-3′.
TCGA microarray data analysis
The available data for gene expression, miRNA expression, and methylation were downloaded from the TCGA data portal (https://tcga-data.nci. nih.gov/tcga/). Microarray data were analyzed using Partek software (Partek Inc.). In the case of gene expression, data generated on Affymetrix microarray platform HT_HG-U133A for 385 tumor and 10 normal samples were subjected to GeneChip robust multiarray averaging (GCRMA) normalization (GCRMA background correction, quantile normalization, log 2 transformation, and median polish probe set summarization). For miRNA expression, we used previously normalized TCGA level 2 data from 426 tumor samples and 10 normal samples run on Agilent's miRNA microarray. For methylation profile, we imported TCGA level 2 data for 111 tumor samples from HumanMethylation450 into Partek and analyzed the intensity of the methylation probes.
Cell viability analysis
Cell viability was determined using the BD Biosciences kit for annexin/ propidium iodide (PI) staining (#556547) according to the manufacturer's instructions. Briefly, supernatant collected from dead or floating cells was combined with trypsinized adherent cells. The cells were consolidated, washed in phosphate-buffered saline, stained for 15 min, and assessed by fluorescence-activated cell sorting. Cells undergoing apoptosis were the percentage of cells that were positive for both annexin V-fluorescein isothiocyanate and PI staining.
Statistics
Statistical significance was assessed using Student's unpaired t test for generating P values. P < 0.05 was considered statistically significant.
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